A roundup of exits, including IPOs and acquisitions, across the tech transfer ecosystem.
Rewrite Therapeutics, a US-based DNA writing technologies spinout of University of California, Berkeley, has been acquired by genome editing company Intellia Therapeutics for $45m in an upfront payment and up to an additional $155m in milestone payments through a mix of stock and cash. Rewrite Therapeutics was founded in 2016. It raised $2m in a seed round led by Civilization Ventures and backed by Prefix Capital and Cystic Fibrosis Foundation in September 2021, according to deals database PitchBook.
StreetLight Data,…